Enoxaparin is a medication used to treat blood clots. It belongs to the class of low molecular weight heparins (LMWH) and works by inhibiting certain clotting factors in the blood. This helps to reduce the risk of conditions such as deep vein thrombosis, pulmonary embolism, and clot formation in patients with certain medical conditions or those undergoing surgery.

Enoxaparin is typically administered via injection under the skin and is available under various brand names. While generally effective, it may cause aftereffects such as bleeding, bruising, and allergic reactions in some individuals. Following dosage instructions and reporting unusual symptoms to a healthcare provider is essential.

Top Enoxaparin Injection Manufacturing Companies in India

Torso Healthcare

Torso Healthcare is one of India’s leading enoxaparin injection manufacturers, specializing in pharmaceutical injectables. The company was established in 2021 and has a manufacturing facility in Baddi, Himachal Pradesh. Torso Healthcare offers a variety of injectable products, such as antibiotics, antifungals, analgesics, anti-inflammatory, antiviral, oncology, and hormonal preparations. The company is ISO 9001:2015 certified and follows the WHO-GMP guidelines for quality assurance. Torso Healthcare also provides services like contract manufacturing and third-party manufacturing of injectables for Indian and international clients.

Alkem Laboratories Limited

Alkem Laboratories Limited, established in 1973, is headquartered in Mumbai, Maharashtra. Their Baddi facility is located in Village Katha, Tehsil Nalagarh, Distt. Solan, Himachal Pradesh. Alkem Laboratories is certified by the World Health Organization (WHO). Alkem is renowned for its commitment to producing high-quality pharmaceutical products, ensuring adherence to stringent global manufacturing and quality control standards.

Cipla Limited

Cipla Limited, a pioneer in the Indian pharmaceutical industry since its inception in 1935, is headquartered in Mumbai – their Baddi plant is situated at Village Kishanpura, Paonta Sahib Road, Baddi, Himachal Pradesh. Cipla Limited holds certification from the World Health Organization (WHO). Cipla is renowned for its innovative healthcare solutions and commitment to making medications accessible worldwide while maintaining the highest quality standards.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, founded in 1977 with its corporate office in Mumbai, is a leading player in the pharmaceutical industry. Their Baddi facility is located at Village Bhatauli Kalan, Baddi, Himachal Pradesh. Glenmark Pharmaceuticals Limited is certified by the World Health Organization (WHO). Glenmark is recognized for its focus on research and development, delivering innovative and affordable healthcare solutions globally while upholding rigorous quality standards.

Mankind Pharma Limited

Mankind Pharma Limited, established in 1995 and headquartered in New Delhi, is a prominent pharmaceutical company known for affordable healthcare solutions. Their Baddi unit is located at Village Bhagwanpura, Baddi, Himachal Pradesh. Mankind Pharma Limited is certified by the World Health Organization (WHO) for Good Manufacturing Practices (GMP). Mankind Pharma is dedicated to ensuring the highest quality and efficacy standards in its products, serving millions of patients worldwide.

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1983 by Dilip Shanghvi, it has become one of the largest pharmaceutical companies in India and ranks amongst the top companies globally. Sun Pharma operates manufacturing facilities across India, including in Gujarat, Maharashtra, and Tamil Nadu. It holds certifications from regulatory bodies such as the US Food and Drug Administration and the European Medicines Agency.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. Established in 1959, it specializes in producing and marketing a wide range of generic and branded pharmaceuticals, including cardiovascular, central nervous system, gastrointestinal, and anti-infective drugs. Torrent is renowned for its focus on quality, innovation, and affordability in healthcare solutions.

Unichem Laboratories Limited

Unichem Laboratories Limited is a global pharmaceutical company headquartered in Mumbai, India. Established in 1944, it focuses on research, development and manufacturing of a broad range of pharmaceutical products. Unichem operates in various therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, and anti-infective drugs, serving markets worldwide with a commitment to quality and innovation.

Common Medical Applications of Enoxaparin Injection

Enoxaparin Injection is a medication belonging to the class of anticoagulants, specifically low molecular weight heparins (LMWH). It is derived from heparin, a naturally occurring anticoagulant found in the body. Enoxaparin works by inhibiting the activity of certain blood clotting factors, thus preventing blood clot formation. This medication is widely used in various medical settings for its efficacy in preventing and treating thromboembolic disorders. Its convenient dosing regimen and relatively lower risk of side effects than traditional unfractionated heparin make it a preferred choice in many clinical scenarios.

Medical Applications of Enoxaparin Injection

Deep Vein Thrombosis (DVT) Prophylaxis

Enoxaparin is frequently prescribed to prevent deep vein thrombosis, particularly in patients undergoing major surgeries such as hip or knee replacement surgery. It lowers the risk of blood clot formation in the deep veins of the legs, which can potentially lead to fatal complications such as pulmonary embolism.

Treatment of Pulmonary Embolism (PE)

Enoxaparin is used as part of the initial treatment regimen for patients diagnosed with pulmonary embolism, a severe condition characterized by the existence of blood clots in the pulmonary arteries. By preventing further clot formation and facilitating the body’s natural clot-dissolving mechanisms, Enoxaparin helps stabilize the patient while other therapies are initiated.

Acute Coronary Syndrome (ACS)

In patients with acute coronary syndrome, which includes conditions such as unstable angina and myocardial infarction, Enoxaparin is often administered in conjunction with other anticoagulant and antiplatelet medications. It helps stop the progression of coronary artery blockage and reduces the risk of recurrent cardiac events.

Prophylaxis in Medical Patients

Hospitalized patients at increased risk of developing blood clots due to immobility, surgery, or certain medical conditions may receive Enoxaparin as prophylactic therapy. This helps prevent venous thromboembolism (VTE) and its associated complications during their hospital stay.

Treatment of Peripheral Arterial Occlusive Disease (PAOD)

Enoxaparin may be used as part of the treatment regimen for peripheral arterial occlusive disease, a condition characterized by the narrowing or blockage of arteries in the limbs. Enoxaparin can alleviate symptoms and reduce the risk of complications such as limb ischemia and gangrene by preventing clot formation and improving blood flow.

Overall, the medical applications of enoxaparin injection encompass a broad spectrum of thromboembolic disorders, making it a valuable tool in the treatment of these potentially life-threatening conditions.

Benefits of Enoxaparin Injection

Enoxaparin, commonly marketed under the name Lovenox, is a medication belonging to the class of anticoagulants, specifically low molecular weight heparins (LMWH). It is widely prescribed for preventing and treating various blood clotting disorders. Enoxaparin works by inhibiting the activity of certain clotting factors in the blood, thereby reducing the risk of clot formation. Below are some of the key benefits associated with the use of Enoxaparin injection:

1. Highly Effective: Enoxaparin prevents and treats blood clots, offering reliable anticoagulation therapy for many conditions, from deep vein thrombosis to acute coronary syndromes.
2. Rapid Onset of Action: Enoxaparin has a relatively rapid onset of action compared to other anticoagulants, providing quick therapeutic effects that are significant in acute situations like myocardial infarction or pulmonary embolism.
3. Predictable Pharmacokinetics: Enoxaparin exhibits predictable pharmacokinetics, allowing for easier dosing regimens and reduced need for frequent monitoring compared to unfractionated heparin.
4. Lower Risk of Heparin-Induced Thrombocytopenia (HIT): Enoxaparin has a lower risk of inducing heparin-induced thrombocytopenia compared to unfractionated heparin, making it a safer choice for many patients requiring anticoagulation therapy.
5. Convenience of Administration: Enoxaparin is typically administered subcutaneously, which can be more convenient for patients than intravenous administration, reducing hospitalization and allowing for outpatient management in many cases.
6. Reduced Risk of Osteoporosis: Unlike other anticoagulants like warfarin, which can contribute to bone loss, Enoxaparin has a lower risk of osteoporosis, making it a preferable option for long-term anticoagulation in specific patient populations.
7. Lower Risk of Bleeding Complications: While all anticoagulants carry a risk of bleeding, Enoxaparin has been associated with a lower risk of major bleeding compared to unfractionated heparin, mainly when used in appropriate doses.
8. Compatibility with Pregnancy: Enoxaparin is often used in pregnant women with thrombophilia or other high-risk conditions, as it does not cross the placenta in significant amounts and is safe for both the mother and the fetus when used as directed.
9. Durable Anticoagulation: Enoxaparin’s relatively long half-life allows for less frequent dosing compared to unfractionated heparin, providing sustained anticoagulation with fewer administrations, which can improve patient compliance and overall therapeutic outcomes.
10. Wide Range of Indications: Enoxaparin is approved in various clinical scenarios, including preventing and treating multiple thrombotic disorders. It is a versatile option for healthcare providers managing patients with different medical conditions requiring anticoagulation therapy.

In conclusion, Enoxaparin injection is a pivotal medication in preventing and treating diverse thromboembolic disorders, offering many benefits ranging from high effectiveness to predictable pharmacokinetics. Among India’s top Enoxaparin sodium injection manufacturers, Torso Healthcare emerges as a prominent player in ensuring the availability of quality Enoxaparin injections. With its state-of-the-art manufacturing facility and adherence to global quality standards, Torso Healthcare exemplifies a commitment to delivering reliable pharmaceutical solutions. Including Torso Healthcare in the landscape of Enoxaparin 60 mg manufacturing in India further enriches the options available to healthcare providers. It underscores the collective effort toward enhancing patient care and safety.